ĐÁNH GIÁ HIỆU QUẢ BAN ĐẦU KIỂM SOÁT CẬN THỊ TRÊN TRẺ EM BẰNG ATROPIN 0.01%

Abstract

Objective: Assessing the initial effectiveness of myopia control by Atropin 0.01% on rapidly increasing myopia children and find out some factors related to the effectiveness of myopia control with Atropin 0.01%. Research methods: clinical trial studies without control group, the study was conducted on 54 eyes with a myopia progress rate of over 1,00 D/year in the refraction department of Vietnam National Eye Hospital. Results: All cases after using Atropin 0.01% were no glare, redness, and difficulty in near vision. Myopia progress rate: after 6 months of using Atropin 0.01%, the average rate of increase in myopia power was 0.62 ± 0.69 D/year, after 12 months of using the drug, the average rate of increase in myopia power was 0.47 ± 0.43 D/ year. Axis length: after 6 months it was longer 0.18 ± 0.11mm (p<0.001), compared to 6 months, after 12 months it was longer 0.15 ± 0.82mm (p>0.05). The accommondation amplitude decreased after 2 weeks of using Atropin 0.01%, recovered after 6 months and 12 months of dropping the drug. The pupil size dilated slightly after 2 weeks of using Atropin 0.01%, recovered after 6 months and 12 months of dropping the drug. Conclusion: After using Atropin 0.01% in myopia children, the rate of myopia progress decreased and near vision was not affectted.